Results 21 to 30 of about 15,674 (165)

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis

BMC Cancer, 2018
Background Clinical trial (CT) participation may confer access to new, potentially active agents before their general availability. This study aimed to investigate the potential survival benefit of participation in investigational CTs of novel hormonal ...
Kyo Chul Koo, Jong Soo Lee, Jong Won Kim, Kyung Suk Han, Kwang Suk Lee, Do Kyung Kim, Yoon Soo Ha, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung   +9 more
doaj   +1 more source

Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review

Prostate International, 2020
New classification systems based on molecular features have been introduced to improve precision medicine for prostate cancer (PCa). This review covers the increasing risk of PCa and the differences in response to targeted therapy that are related to ...
Jae-Seung Chung, Todd M. Morgan, Sung Kyu Hong   +2 more
doaj   +1 more source

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

BMC Urology, 2023
Background The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant prostate ...
Soichiro Yoshida, Taro Takahara, Yuki Arita, Masaya Ito, Sara Hayakawa, Tomohiko Oguchi, Yoshinobu Komai, Noboru Numao, Takeshi Yuasa, Masaharu Inoue, Hiroki Ushijima, Shigehiro Kudo, Yasumasa Shimano, Yuki Nakamura, Yusuke Uchida, Sho Uehara, Hajime Tanaka, Hiroshi Yaegashi, Kouji Izumi, Minato Yokoyama, Yoh Matsuoka, Yasuo Yoshioka, Koji Konishi, Katsuyuki Nakanishi, Akira Nagahara, Akihiro Hirakawa, Ryuji Koike, Fumitaka Koga, Kazuo Nishimura, Atsushi Mizokami, Junji Yonese, Yukio Kageyama, Ryoichi Yoshimura, Yasuhisa Fujii   +33 more
doaj   +1 more source

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen.
Nakagami Y, Ohnuma S, Tamaoka M, Inoue T, Yamagishi M, Oshinomi K, Nagata M, Oohira Y, Yamochi T, Fukagai T.   +9 more
europepmc   +2 more sources

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy

IJU Case Reports, 2021
Introduction The efficacy of salvage local therapy after external beam radiotherapy has recently gained attention. However, a challenge with these therapies is the risk of significant genitourinary and gastrointestinal toxicity.
Soichiro Yoshida, Yoh Matsuoka, Kazuma Toda, Sho Uehara, Hajime Tanaka, Minato Yokoyama, Kazutaka Saito, Ryoichi Yoshimura, Yasuhisa Fujii   +8 more
doaj   +1 more source

Clinicopathological Features, Treatment, and Outcome of Omani Patients with Metastatic Prostate Cancer

Oman Medical Journal, 2022
Objectives: Prostate cancer (PCa) is the third most common cancer worldwide, with its incidence rising in the Middle East. There is a paucity of data about the clinicopathological features and outcomes of metastatic prostate cancer (mPCa) from the Middle
Shiyam Kumar, Ikram A. Burney, Joseph Kunju, Mohammed Salim Al-Marhoon, Khurrum Mutahir Siddiqui   +4 more
doaj   +1 more source

MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer

Research and Reports in Urology, 2022
Nicolas Fernandez,1 Julian Chavarriaga,2 Paola Ayala,3 Adriana Pedraza,4 John Bolivar,5 Juan Guillermo Prada,6 Juan Guillermo Cataño,6 Herney Garcia,7 Juliana Villanueva,6 Daniela Varela,6 Ignacio Zarante3 1Division of Urology Seattle Children’s Hospital,
Fernandez N, Chavarriaga J, Ayala P, Pedraza A, Bolivar J, Prada JG, Cataño JG, Garcia H, Villanueva J, Varela D, Zarante I   +10 more
doaj  

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Cancer Medicine, 2020
Background Recently approved second‐generation androgen receptor inhibitors (SGARIs) for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles.
Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Jui‐Hua Tsai, Jarjieh Fang, A. Reginald Waldeck, Stacey J. Simmons   +9 more
doaj   +1 more source

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castrationresistant prostate cancer: Post hoc analysis of Korean patients [PDF]

Investigative and Clinical Urology, 2016
Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial.
Choung-Soo Kim, Ad Theeuwes, Dong Deuk Kwon, Young Deuk Choi, Byung Ha Chung, Hyun Moo Lee, Kang Hyun Lee, Sang Eun Lee   +7 more
doaj   +1 more source

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy

Prostate International, 2014
Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa).
Inna Armandari, Agus Rizal Hamid, Gerald Verhaegh, Jack Schalken   +3 more
doaj   +1 more source